Biomedical subjects
J Bury
Publications and source records attributed to J Bury.
Immunonephelometric quantitation of the apolipoprotein C-III in human plasma.
A quantitative assay, based on endpoint immunonephelometry, was developed for human apolipoprotein C-III (Apo C-III) in plasma and lipoprotein fractions. The standard curve was constructed either with purified Apo C-III2 as a primary standard or with plasma as a secondary standard. It was linear between 50 and 400 ng Apo C-III per sample, corresponding to 1 microliter undiluted plasma. The intra- and interassay coefficients of variation (CV values) were 2.2 and 6.3%, respectively. The Apo C-III immunoreactivity was not influenced by detergents, denaturants nor by delipidation. The use of a non-ionic detergent (Apovax, 0.1 g/l) avoided the need for organic solvent extraction for plasma containing up to 4 g of triglycerides/l by reducing the sample turbidity. As measured in 126 normolipidemic subjects, the plasma Apo C-III concentration was 0.118 +/- 0.028 g/l (mean +/- SD). Apo C-III concentrations were only slightly elevated in patients with Fredrickson type IIa hyperlipoproteinaemia. The Apo C-III levels were nearly 3 times higher in type I, IIb, III and IV patients, while subjects with type V hyperlipaemia had about a 5-fold increase in Apo C-III compared to the healthy. The plasma Apo C-III values were strongly correlated with the plasma triglyceride concentrations (r = 0.80, n = 201). The Apo C-III distribution among the various lipoprotein fractions showed a higher proportion of Apo C-III in VLDL in hypertriglyceridaemic subjects compared to normolipaemic subjects.
Acquisition of the heat-shock response and thermotolerance during early development of Xenopus laevis.
The ability to synthesize a 68,000- to 70,000-Da protein (hsp) in heat-shocked early Xenopus laevis embryos is dependent on the stage of development. Whereas late blastula and later stage embryos synthesize hsp68-70 after heat shock, cleavage stages are incompetent with respect to hsp synthesis. In vitro translation experiments and RNA blot analyses demonstrate that enhanced synthesis of hsp68-70 is associated with an accumulation of hsp68-70 mRNA. Examination of the effect of heat shock on preexisting actin mRNA reveals that heat shock promotes a reduction in the levels of actin mRNA in cleavage embryos but has no discernible effect on actin mRNA levels in neurula embryos. Finally, the acquisition of the heat-shock response (i.e., synthesis of hsp68-70 and accumulation of hsp70 mRNA) during early Xenopus development is correlated with the acquisition of thermotolerance.
Hyperthyroidism influences the distribution and apolipoprotein A composition of the high density lipoproteins in man.
Hyperthyroidism has a different influence on the major high density lipoprotein (HDL) components cholesterol, apoprotein (apo) A-I, and apo A-II. To characterize in greater detail the alterations induced by hyperthyroidism within the HDL subclasses, we investigated HDL distribution and composition in 11 hyperthyroid women before and during treatment. The plasma concentrations of total cholesterol, HDL cholesterol, phospholipids, apo A-I, and apo B were decreased when the patients were hyperthyroid compared with the values during treatment. Apo A-II and apo C-III levels were only slightly lower in the hyperthyroid state. Triglyceride and apo E concentrations did not change significantly during therapy. Analysis of lipoprotein subclasses separated by isopycnic ultracentrifugation revealed 1) marked decreases in low density lipoprotein (LDL) cholesterol, phospholipids, and apo B; 2) less pronounced reductions in the very low density lipoprotein (VLDL) lipid and apo B concentrations; and 3) a consistent decrease in the HDL2b (density, 1.063-1.100 g/ml) fraction in the hyperthyroid patients. The reduction in HDL2b mass was associated with lower concentrations of HDL2b cholesterol, phospholipids, and apo A-I. The HDL2b apo A-II levels remained constant during treatment. Hyperthyroidism, therefore, modified the apo A composition of the HDL2b particles and resulted in a decreased molar apo A-I to apo A-II ratio within HDL2b. Further analysis of HDL particles differing in their apo A composition; i.e. HDL particles containing apo A-I only [(A-I)HDL] or containing both apo A-I and A-II [(A-I + A-II)HDL], by immunological procedures suggested that hyperthyroidism influenced the apo A content of HDL2b mainly by changing the proportions of (A-I)HDL and (A-I + A-II)HDL and the amount of apo A-I associated with (A-I)HDL. Treatment reversed the preferential decrease in (A-I)HDL within the HDL2b subclass. The particle sizes within HDL subfractions, measured by polyacrylamide gradient gel electrophoresis, were similar in the untreated and treated patients. Consequently, the decreased mass of apo A-I and lipids within HDL2b in the hyperthyroid patients could be attributed to a reduced number of identically sized particles within this fraction. These data demonstrate that the thyroid hormones are important regulators of HDL metabolism through their influence on the concentration and distribution of apo A-I.
Enzyme linked immunosorbent assay for human apolipoprotein C-III.
A sandwich enzyme linked immunosorbent assay (ELISA) for apolipoprotein C-III was developed. Anti apolipoprotein C-III immunoglobulins were used both for coating of microtitre plates and for the preparation of an anti apolipoprotein C-III horse-radish peroxidase conjugate. Under optimized assay conditions, the sensitivity lies around 0.3 ng apolipoprotein C-III with a working range of 1 to 6 ng. Standard curves are parallel for purified apolipoprotein C-III, for untreated plasma and for lipoprotein fractions. Delipidation did not affect the content of apolipoprotein C-III in plasma. The assay was evaluated by comparison with an immunonephelometric assay for apolipoprotein C-III, yielding a correlation coefficient of 0.982 (n = 79). The mean intra- and interassay CV for the whole working range of the assay were 3.6% and 4.2% respectively.
Amsacrine with high-dose cytarabine in acute leukemia.
Explore the source record for details and available documents.
Quantification of human serum apolipoprotein AI by enzyme immunoassay.
We developed a quantitative assay for apolipoprotein AI (apo AI) in human serum, using a "sandwich"-type enzyme-linked immunosorbent assay. Diluted serum samples were pipetted into the wells of polystyrene microtiter plates that had been previously coated with purified rabbit anti-human apo AI antibodies. After incubation for 2 h and washing, antibodies conjugated to horseradish peroxidase (EC 1.11.1.7) were added and incubated for 2 h; after further washing, the bound enzyme was assayed by oxidation of o-phenylenediamine. Assay conditions were optimized for the incubation time and the amounts of coating antibodies and conjugate. Assay sensitivity is about 0.5 ng of apo AI, with a working range of 1 to 14 ng, similar to that of radioimmunoassays for human apo AI. The standard curves for apo AI in serum or HDL and for purified apo AI were parallel. Delipidation, heat treatment, or addition of detergents did not affect the amount of immunoassayable apo AI in human serum. The intra- and interassay CVs were 4 and 8%, respectively. Results for 100 serum samples compared well with those by immunonephelometry (r = 0.94).
[A rare complication of ophthalmic zona: spreading cerebral arteritis].
Explore the source record for details and available documents.
Isolation of human apolipoprotein E by high performance liquid chromatography.
Explore the source record for details and available documents.
[The HLA system and bone marrow graft].
Explore the source record for details and available documents.
Isolation and characterization of lipoprotein profiles in newborns by density gradient ultracentrifugation.
Lipoproteins in newborn plasma were isolated from a minimal sample amount (0.3 ml) by a single-step ultracentrifugation in a density gradient, spanning the density range 1.02-1.20 g/ml. After 66 h ultracentrifugation in a swinging-bucket rotor, the content of the tube was eluted and collected in 0.4 ml fractions. Cholesterol and apoproteins AI, AII, and B were assayed in each fraction yielding both the distribution and composition of the very low density lipoprotein (VLDL), low density lipoprotein (LDL), high density lipoprotein (HDL2, HDL3). Newborn plasma was characterized by a low amount of triglyceride-poor and cholesterol ester-rich VLDL and high content of HDL2 and HDL3. The VLDL and LDL concentrations increased drastically between 0 and 7 days together with the triglyceride content of the VLDL. At 30 days the lipid composition of VLDL was similar to that of adults, whereas the lipid/protein content remained low both in VLDL and LDL. The composition of HDL2 and HDL3 remained constant during this period, the percentage of HDL2 being higher in newborns than in adults. These compositional changes were reflected in the microviscosity of the lipoproteins, specially in the VLDL fraction.
Comparison of chemotherapy with immunotherapy for maintenance of acute lymphoblastic leukemia in children and adults.
Two hundred and seventeen patients, 1-50 yr old, with acute lymphoblastic leukemia in complete remission were randomized to receive a 1-yr consolidation chemotherapy of either type P, comprising 7 different drugs, or type M, consisting of methotrexate interspersed with prednisone and vincristine. Thereafter, they were randomized a second time to receive a 4-yr maintenance of either chemotherapy or immunotherapy, comprised of allogeneic blasts and bacillus Calmette-Guérin (BCG). Consolidation P caused more toxicity than consolidation M. However, comparison between the consolidation therapies P and M showed no significant difference, neither for disease-free interval nor for duration of survival. Chemotherapy showed more lethal toxicity in adults than in children. Comparison between chemotherapy (C) and immunotherapy (I) as maintenance treatment showed a significant (p = 0.016) superiority of C for disease-free interval (DFI). The difference was even more pronounced (p = 0.009) in the group with less than 8 g/dl of hemoglobin (Hb) at diagnosis before therapy. On the other hand, for patients with more than 8 g/dl Hb at diagnosis, presumably those with T-ALL, no difference in DFI was seen. No difference has been seen so far between maintenance therapies I and C concerning the duration of survival. The patients who were receiving maintenance I when they relapsed and who were consequently retreated by chemotherapy, survived longer from relapse than those patients retreated for relapse while receiving maintenance C.
[Neurodysleptic syndrome induced by domperidone].
Explore the source record for details and available documents.
[Warning signs of malignant hemopathies].
Explore the source record for details and available documents.
[Vidarabine: an active antiherpetic treatment by parenteral administration].
Explore the source record for details and available documents.
P1 incompatibility in pigeon breeders.
Pigeon breeders of the P2 blood phenotype may develop anti-P1 haemagglutinins as a consequence of natural immunization to pigeon dust. The half-life of labelled P1 erythrocytes was determined in two P2 pigeon breeders otherwise compatible except for the presence of anti-P1 antibodies and in four compatible controls without anti-P1. The half-life of tagged cells was within the normal range in one breeder but significantly reduced in the other, indicating that P1 incompatibility may occur in vivo. Since anti-P1 antibodies are found in about 20% of P2 pigeon breeders, it is suggested that this group may be prone to developing an incompatibility to transfused P1 red cells.
Control of platelet territory development in megakaryocytes.
Explore the source record for details and available documents.